Citigroup Inc Abb Vie Inc. Call Options Transaction History

Citigroup Inc

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$163.84 - $199.33 $7.96 Million - $9.69 Million	48,600 Added 18.46%	311,900 $61.6 Million
Q2 2024 Aug 12, 2024	SELL	$154.79 - $180.76 $14.8 Million - $17.3 Million	-95,900 Reduced 26.7%	263,300 $45.2 Million
Q1 2024 May 10, 2024	SELL	$159.82 - $182.1 $78.2 Million - $89.1 Million	-489,400 Reduced 57.67%	359,200 $65.4 Million
Q4 2023 Feb 09, 2024	BUY	$137.6 - $154.97 $6.07 Million - $6.83 Million	44,100 Added 5.48%	848,600 $132 Million
Q3 2023 Nov 09, 2023	BUY	$133.59 - $154.65 $84.8 Million - $98.1 Million	634,500 Added 373.24%	804,500 $120 Million
Q2 2023 Aug 10, 2023	BUY	$132.51 - $164.9 $9.3 Million - $11.6 Million	70,200 Added 70.34%	170,000 $22.9 Million
Q1 2023 May 11, 2023	SELL	$144.61 - $166.54 $10.4 Million - $12 Million	-71,800 Reduced 41.84%	99,800 $15.9 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $373,437 - $447,849	-2,700 Reduced 1.55%	171,600 $27.7 Million
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $8.35 Million - $9.57 Million	-62,200 Reduced 26.3%	174,300 $23.4 Million
Q2 2022 Aug 10, 2022	SELL	$137.62 - $174.96 $74 Million - $94 Million	-537,400 Reduced 69.44%	236,500 $36.2 Million
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $32.7 Million - $40.6 Million	-247,900 Reduced 24.26%	773,900 $125 Million
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $6.77 Million - $8.56 Million	63,000 Added 6.57%	1,021,800 $138 Million
Q3 2021 Nov 10, 2021	BUY	$106.4 - $120.78 $102 Million - $116 Million	958,800 New	958,800 $103 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.